Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07700004
Starting soon Observational

The King's Brief Lnterstitial Lung Disease Questionnaire

NCT07700004 · tracked via the Priya Life Science Turkey tracker
Sponsor
Pamukkale University
Phase
Observational
Started
2026-07-05
Last updated
2026-07-13

Condition(s) studied

Interstitial Lung Disease Due to Systemic Disease

Investigational drug(s) / intervention(s)

patient reported outcome measures

patient reported outcome measures: King's Brief lnterstitial Lung Disease Questionnaire, Arthritis Impact Measurement Scales (AIMS2)-Short Form, Modified Medical Research Council (mMRC) Dyspnea Scale, Visual Analog Scale were evaluated.

Study summary

The aim of this study is to examine the validity and reliability of the Turkish Validity and Reliability of The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) in Individuals with Interstitial Lung Involvement Secondary to Rheumatological Diseases.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:-Having been diagnosed with interstitial lung disease by a rheumatologist, * Being 18 years of age or older, * Agreeing to participate in the study. Exclusion Criteria:- Presence of a neurological disease * Presence of any orthopedic problem that affects functionality * History of any orthopedic surgery in the last year * Inability to speak or understand Turkish fluently * Presence of a psychiatric illness that affects cooperation * Heart failure that affects daily living activities * Being a cancer patient

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Usak University Uşak Center

More Pamukkale University trials in Turkey

Clinical Evaluation of Two Different Surgical Techniques With PRF in the Treatment of Multiple Gingival Recessions Starting soon
The Effect of RF Genicular Nerve Block Applied in the Preoperative Period on Fast-track Total Knee Arthroplasty Recruiting
"Core Stabilization Strenght and Pelvic Floor Functions in Primary Sjogren's" Enrolling by invitation
Comparison of the Efficacy of Perineal and Anal Electrical Stimulation in Patients with Urinary Incontinence After Radical Prostatectomy Starting soon
Dysphagia Risk in Rheumatic Diseases Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07700004 on ClinicalTrials.gov ↗ ← All trials in Turkey